Suppressive action of melatonin on the TH-2 immune response in rats infected with Trypanosoma cruzi

Journal of Pineal Research

Volumn 45, Issue 3, 2008, Pages 291-296

  Santello, Fabricia Helena ^a   Frare, Eduardo Osório ^a   Dos Santos, Carla Domingues ^a   Caetano, Leony Cristina ^a   Alonso Toldo, Míriam Paula ^a   Do Prado Jr , José Clóvis ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

IL 10; IL 4; Immunity; Splenocyte; TGF ; Trypanosoma cruzi

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 4; MELATONIN; MELATONIN RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; IMMUNE RESPONSE; IMMUNOMODULATION; INNATE IMMUNITY; MACROPHAGE; MALE; NONHUMAN; PROTEIN BLOOD LEVEL; RAT; SPLEEN CELL; T LYMPHOCYTE; TRYPANOSOMA CRUZI; TRYPANOSOMIASIS;

ANALYSIS OF VARIANCE; ANIMALS; CHAGAS DISEASE; CONCANAVALIN A; CYTOKINES; IMMUNITY, ACTIVE; IMMUNITY, INNATE; INTERLEUKIN-10; INTERLEUKIN-4; MACROPHAGES; MELATONIN; PARASITEMIA; RATS; RATS, WISTAR; TH1 CELLS; TH2 CELLS; TRANSFORMING GROWTH FACTOR BETA; TRYPANOSOMA CRUZI;

EID: 51649088011     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/j.1600-079X.2008.00589.x     Document Type: Article

References (57)

1. WHO. Control of Chagas Disease. World Health Organization Technical Report Series no. 811. WHO, Geneva, 2002.
2. Teixeira MM, Gazzinelli RT, Silva JS. Chemokines, inflammation and Trypanosoma cruzi infection. Trends Parasitol 2002 18: 262 265.
3. Moncayo A. Progress towards the elimination of transmission of Chagas disease in Latin America. World Health Stat Q 1997 50: 195 198.
4. Braga MS, Lauria-Pires L, Arganaraz ER et al. Persistent infections in chronic Chagas disease patients treated with anti-Trypanosoma cruzi nitroderivatives. Rev Inst Med Trop São Paulo 2000 42: 157 161.
5. Sacks D, Sher A. Evasion of innate immunity by parasitic protozoa. Nat Immunol 2002 3: 1041 1047.
6. Dos Reis GA, Freire-De-Lima CG, Nunes MP et al. The importance of aberrant T-cell responses in Chagas disease. Trends Parasitol 2005 21: 237 243.
7. Martin DL, Weatherly DB, Laucella SA et al. CD8+ T-cell responses to Trypanosoma cruzi are highly focused on strain-variant trans-sialidase epitopes. PLoS Pathog 2006 2: e77.
8. Ouaissi A, Ouaissi M. Molecular basis of Trypanosoma cruzi and Leishmania interaction with their host(s): exploitation of immune and defense mechanisms by the parasite leading to persistence and chronicity, features reminiscent of immune system evasion strategies in cancer diseases. Arch Immunol Ther Exp (Warsz) 2005 53: 102 114.
9. Prata A. Clinical and epidemiological aspects of Chagas disease. Lancet Infect Dis 2001 1: 92 100.
10. Viotti R, Vigliano C, Armenti H et al. Treatment of chronic Chagas disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up. Am Heart J 1994 127: 151 162.
11. Qin S, Rottman JB, Myers P et al. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest 1998 101: 746 754.
12. Kuma S, Tarleton RL. The relative contribution of antibody production and CD8+ T cell function to immune control of Trypanosoma cruzi. Parasite Immunol 1998 20: 207 216.
13. Tarleton RL, Grusby MJ, Postan M et al. Trypanosoma cruzi infection in MHC-deficient mice: further evidence for the role of both class I- and class II-restricted T cells in immune resistance and disease. Int Immunol 1996 8: 13 22.
14. Tarleton RL, Grusby MJ, Zhang L. Increased susceptibility of Stat4-deficient and enhanced resistance in Stat6-deficient mice to infection with Trypanosoma cruzi. J Immunol 2000 165: 1520 1525.
15. Wizel B, Nunes M, Tarleton RL. Identification of Trypanosoma cruzi trans-sialidase family members as targets of protective CD8+ TC1 responses. J Immunol 1997 159: 6120 6130.
16. Morera AL, Abreu P. Seasonality of psychopathology and circannual melatonin rhythm. J Pineal Res 2006 41: 279 283.
17. Navara KJ, Nelson RJ. The dark side of light at night: physiological, epidemiological, and ecological consequences. J Pineal Res 2007 43: 215 224.
18. Reiter RJ, Melchiorri D, Sewerynek E et al. A review of the evidence supporting melatonin's role as an antioxidant. J Pineal Res 1995 18: 1 11.
19. Tan DX, Manchester LC, Terron MP et al. One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species? J Pineal Res 2007 42: 28 42.
20. Hardeland R, Backhaus C, Fadavi A. Reactions of the NO redox forms NO+, *NO and HNO (protonated NO-) with the melatonin metabolite N1-acetyl-5-methoxykynuramine. J Pineal Res 2007 43: 382 388.
21. Manda K, Ueno M, Anzai K. AFMK, a melatonin metabolite, attenuates X-ray-induced oxidative damage to DNA, proteins and lipids in mice. J Pineal Res 2007 42: 386 393.
22. Carrillo-Vico A, Guerrero JM, Lardone PJ, Reiter RJ. A review of the multiple actions of melatonin on the immune system. Endocrine 2005 27: 189 200.
23. Yellon SM. Melatonin mediates photoperiod control of endocrine adaptations and humoral immunity in male Siberian hamsters. J Pineal Res 2007 43: 109 114.
24. Reiter RJ. The melatonin rhythm: both a clock and a calendar. Experientia 1993 49: 654 664.
25. Solomon G. Psychoneuroimmunology: interactions between central nervous system and immune system. J Neurosci Res 1987 18: 1 9.
26. Wahl SM. Transforming growth factor-β: the good, the bad and the ugly. J Exp Med 1994 180: 1587 1590.
27. Espevik T, Figari IS, Shalaby MR et al. Inhibition of cytokine production by cyclosporin A and transforming growth factor-β. J Exp Med 1987 166: 571 576.
28. Bellone G, Aste-Amezaga M, Trinchieri G et al. Regulation of NK cell functions by TGF-β1. J Immunol 1995 155: 1066 1073.
29. Nandan D, Reiner NE. TGF-β attenuates the class II transactivator and reveals an accessory pathway of IFN-γ action. J Immunol 1997 158: 1095 1101.
30. Omer FM, Kurtzhals JA, Riley EM. Maintaining the immunological balance in parasitic infections: a role for TGF-beta? Parasitol Today 2000 16: 18 23.
31. Holscher C, Mohrs M, Dai WJ et al. Tumor necrosis factor alpha-mediated toxic shock in Trypanosoma cruzi-infected interleukin 10-deficient mice. Infect Immun 2000 68: 4075 4083.
32. Hunter CA, Ellis-Neyes LA, Slifer T et al. IL-10 is required to prevent immune hyperactivity during infection with Trypanosoma cruzi. J Immunol 1997 158: 3311 3316.
33. Hoft DF, Lynch RG, Kirchhoff LV. Kinetic analysis of antigen-specific immune responses in resistant and susceptible mice during infection with Trypanosoma cruzi. J Immunol 1993 151: 7038 7047.
34. Minoprio P, El-Cheikh MC, Murphy E et al. Immunobiology of murine T. cruzi infection: the predominance of parasite-nonspecific responses and the activation of TCRI T cells. Immunol Rev 1989 112: 183 207.
35. Reed SG, Brownell CE, Russo DM et al. IL-10 mediates susceptibility to Trypanosoma cruzi infection. J Immunol 1994 153: 3135 3140.
36. Silva JS, Morrissey PJ, Grabstein KH et al. Interleukin 10 and interferon gamma regulation of experimental Trypanosoma cruzi infection. J Exp Med 1992 175: 169 174.
37. Zhang L, Tarleton RL. Characterization of cytokine production in murine Trypanosoma cruzi infection by in situ immunocytochemistry: lack of association between susceptibility and type 2 cytokine production. Eur J Immunol 1996 26: 102 109.
38. Kühn R, Löhler J, Rennick D et al. Interleukin-10 deficient mice develop chronic enterocolitis. Cell 1993 75: 263 274.
39. Silva LHP, Nussenzweig V. Sobre uma cepa de Trypanosoma cruzi altamente virulenta para o camundongo branco. Folia Clin Biol 1953 20: 191 201.
40. Brener Z. Therapeutic activity and criterion of cure in mice experimentally infected with Trypanosoma cruzi. Rev Inst Med Trop São Paulo 1962 4: 389 396.
41. Viveros-Paredes JM, Puebla-Pérez AM, Gutiérrez-Coronado O et al. Dysregulation of the Th1/Th2 cytokine profile is associated with immunosuppression induced by hypothalamic-pituitary-adrenal axis activation in mice. Int Immunopharmacol 2006 6: 774 781.
42. Plata F, Wietzerbin J, Pons FG et al. Synergistic protection by specific antibodies and interferon against infection by Trypanosoma cruzi in vitro. Eur J Immunol 1984 14: 930 935.
43. Wirth JJ, Kierszenbaum F, Sonnenfeld G et al. Enhancing effects of gamma interferon on phagocytic cell association with and killing of Trypanosoma cruzi. Infect Immun 1985 49: 61 66.
44. Golden JM, Tarleton RL. Trypanosoma cruzi: cytokine effects on macrophage trypanocidal activity. Exp Parasitol 1991 72: 391 402.
45. Munoz-Fernandez MA, Fernandez MA, Fresno M. Synergism between tumor necrosis factor-alpha and interferon-gamma on macrophage activation for the killing of intracellular Trypanosoma cruzi through a nitric oxide-dependent mechanism. Eur J Immunol 1992 22: 301 307.
46. Liblau R, Singer S, Mcdevitt H. Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol Today 1995 16: 34 38.
47. Nishimura T, Ohta A. A critical role for antigen-specific Th1 cells in acute liver injury in mice. J Immunol 1999 162: 6503 6509.
48. Petrovsky N. Towards a unified model of neuroendocrine-immune interaction. Immunol Cell Biol 2001 79: 350 357.
49. Wirth JJ, Kierszenbaum F, Zlotnik A. Effects of IL-4 on macrophage functions: increased uptake and killing of a protozoan parasite (Trypanosoma cruzi). Immunology 1989 66: 296 301.
50. Abrahamsohn IA, Da Silva AP, Coffman RL. Effects of interleukin-4 deprivation and treatment on resistance to Trypanosoma cruzi. Infect Immun 2000 68: 1975 1979.
51. Mosmann TR. Properties and functions of interleukin-10. Adv Immunol 1994 56: 1 26.
52. Santello FH, Frare EO, Dos Santos CD et al. Melatonin treatment reduces the severity of experimental Trypanosoma cruzi infection. J Pineal Res 2007 42: 359 363.
53. Reed SG. TGF-β in infections and infectious diseases. Microbes Infect 1999 1: 1313 1325.
54. Barral-Netto M, Barral A, Brownell CE et al. Transformation growth factor-β in Leishmania infection: a parasite escape mechanism. Science 1992 257: 545 548.
55. Ming M, Ewen ME, Pereira ME. Trypanosome invasion of mammalian cells requires activation of the TGF beta signaling pathway. Cell 1995 82: 287 296.
56. Seabra SH, De Souza W, Da Matta RA. Toxoplasma gondii exposes phosphatidylserine that induces a TGF-β autocrine effect orchestrating macrophages evasion. Biochem Biophys Res Commun 2004 324: 744 752.
57. Abrahamsohn IA, Coffman RL. Cytokine and nitric oxide regulation of the immunosuppression in Trypanosoma cruzi infection. J Immunol 1995 155: 3955 3963.